A detailed history of Nissay Asset Management Corp transactions in United Therapeutics Corp stock. As of the latest transaction made, Nissay Asset Management Corp holds 5,280 shares of UTHR stock, worth $2.12 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
5,280
Previous 5,402 2.26%
Holding current value
$2.12 Million
Previous $1.24 Million 35.56%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$228.26 - $319.04 $27,847 - $38,922
-122 Reduced 2.26%
5,280 $1.68 Million
Q1 2024

May 15, 2024

BUY
$210.76 - $249.51 $18,968 - $22,455
90 Added 1.69%
5,402 $1.24 Million
Q4 2023

Feb 14, 2024

BUY
$214.88 - $256.94 $46,843 - $56,012
218 Added 4.28%
5,312 $1.17 Million
Q3 2023

Nov 14, 2023

BUY
$211.82 - $248.24 $46,388 - $54,364
219 Added 4.49%
5,094 $1.15 Million
Q2 2023

Aug 14, 2023

BUY
$205.19 - $232.99 $43,705 - $49,626
213 Added 4.57%
4,875 $1.08 Million
Q1 2023

May 15, 2023

BUY
$212.99 - $276.17 $992,959 - $1.29 Million
4,662 New
4,662 $1.04 Million
Q2 2019

Aug 07, 2019

SELL
$76.06 - $120.81 $382,505 - $607,553
-5,029 Closed
0 $0
Q1 2019

May 03, 2019

BUY
$107.15 - $126.84 $15,429 - $18,264
144 Added 2.95%
5,029 $590,000
Q4 2018

Feb 06, 2019

SELL
$101.4 - $128.73 $7,098 - $9,011
-70 Reduced 1.41%
4,885 $532,000
Q3 2018

Oct 30, 2018

BUY
$113.81 - $129.46 $14,795 - $16,829
130 Added 2.69%
4,955 $634,000
Q2 2018

Aug 08, 2018

BUY
$101.14 - $118.31 $12,945 - $15,143
128 Added 2.73%
4,825 $546,000
Q1 2018

May 14, 2018

BUY
$107.21 - $151.94 $14,044 - $19,904
131 Added 2.87%
4,697 $528,000
Q4 2017

Feb 14, 2018

BUY
$118.58 - $151.28 $541,436 - $690,744
4,566
4,566 $676,000

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $18.2B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Nissay Asset Management Corp Portfolio

Follow Nissay Asset Management Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nissay Asset Management Corp , based on Form 13F filings with the SEC.

News

Stay updated on Nissay Asset Management Corp with notifications on news.